[
    [
        {
            "time": "2021-03-15",
            "original_text": "U.S. FDA declines approval of Novartis cholesterol-lowering drug",
            "features": {
                "keywords": [
                    "FDA",
                    "declines",
                    "approval",
                    "Novartis",
                    "cholesterol-lowering",
                    "drug"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "U.S. FDA declines approval of Novartis cholesterol-lowering drug",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-15",
            "original_text": "Novartis receives complete response letter from U.S. FDA for inclisiran",
            "features": {
                "keywords": [
                    "Novartis",
                    "receives",
                    "complete",
                    "response",
                    "letter",
                    "FDA",
                    "inclisiran"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-15",
            "original_text": "Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "FDA",
                    "Emergency",
                    "Nod",
                    "PFE",
                    "BNTX",
                    "COVID-19",
                    "Vaccine",
                    "AZN",
                    "Buy",
                    "ALXN"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]